[{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"U.S FDA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ U.S FDA","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ U.S FDA"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.5,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Aldeyra Therapeutics \/ AbbVie Inc"}]
Find Clinical Drug Pipeline Developments & Deals for Reproxalap
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
